1 |
N.E. Taylor, A.E. Mark, P. Vallat, R.M. Brunne, B. Testa and W.F. Van Gunteren, Solvent dependent conformation and hydrogen bounding capacity of cyclosporin A: evidence from partition coefficient and molecular dynamics simulations, J. Med. Chem., 36, 3753-3764 (1993)
|
2 |
M.H. El-Shabouri, Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A, Int. J. Pharm., 249, 101-108 (2002)
DOI
ScienceOn
|
3 |
E. Ugazio, R. Cavalli and M.R. Gasco, Incorporation of cyclosporin A in solid lipid nanoparticles, Int. J. Pharm., 241, 341-344 (2002)
DOI
ScienceOn
|
4 |
J.L. Italia, V. Bhardwaj and M.N.V.R. Kumar, Diease, destination, dose and delivery aspects of ciclosporin: the state of the art, Drug Disco. Today, 11, 846-854 (2006)
DOI
ScienceOn
|
5 |
D. Faulds, K.L. Goa and P. Benfield, Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders, Drugs, 45, 953-1040 (1993)
DOI
ScienceOn
|
6 |
R.H. Muller, M. Radtke and S.A. Wissing, Nanostructured lipid matrices for improved microencapsulation of drugs, Int. J. Pharm., 242, 121-128 (2002)
DOI
ScienceOn
|
7 |
M. Radtke and R.H. Müller, NLC-nanostructured lipid carriers: the new generation of lipid drug carriers, New Drugs, 2, 48-52 (2001)
|
8 |
J.X. Wang, X. Sun and Z.R. Zhang, Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles, Eur. J. Pharm. Biopharm., 54, 285-290 (2002)
DOI
ScienceOn
|
9 |
Cyclosporin emulsions, US Patent 5660858 (1997)
|
10 |
J.F. Pinto and R.H. Muller, Pellets as carriers of solid lipid nanoparticles ( ) for oral administration of drugs, Pharmazie, 54, 506-509 (1999)
|
11 |
J.L. Italia, D.K. Bhatt, V. Bhardwaj, K. Tikoo and M.N.V. Ravi Kumar, PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral , J. Control. Release, 119, 197-206 (2007)
DOI
ScienceOn
|
12 |
L. Hu, X. Tang and F. Cui, Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs, J. Pharm. Pharmacol., 56, 1527-1535 (2004)
DOI
ScienceOn
|
13 |
P.J. Carrigan and T.R. Bates, Biopharmaceutics of drugs administered in lipid-containing dosage forms I: GI absorption of griseofulvin from an oil-in-water emulsion in the rat, J. Pharm. Sci., 62, 1476-1479 (1973)
DOI
|
14 |
K. Manjunath, V. Venkateswarlu, Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration, J. Drug Target., 14, 632-645 (2006)
DOI
ScienceOn
|
15 |
C. Washington, Stability of lipid emulsions for drug delivery, Adv. Drug Deliv. Rev., 20, 131-145 (1996)
DOI
ScienceOn
|
16 |
Q.Y. Xiang, M.T. Wang, F. Chen, T. Gong, Y.L. Jian, Z.R. Zhang and Y. Huang, Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles, Arch. Pharm.Res., 30, 519-525 (2007)
과학기술학회마을
DOI
ScienceOn
|
17 |
K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann and K. Mader, Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy, J. Control. Release, 95, 217-227 (2004)
DOI
ScienceOn
|
18 |
Y. Li, K.J. Zhu, J.X. Zhang, H.L. Jiang, J.H. Liu, Y.L. Hao, H. Yasuda, A. Ichimaru and K. Yamamoto, In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres, Int. J. Pharm., 295, 67-76 (2005)
DOI
ScienceOn
|